<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472081</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-016</org_study_id>
    <nct_id>NCT01472081</nct_id>
  </id_info>
  <brief_title>Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)</brief_title>
  <official_title>A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine the safety, effectiveness and best dose to use when giving
      Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of
      metastatic renal cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Adverse event (AE)</measure>
    <time_frame>up to 100 days after last dose or longer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Serious adverse event (SAE)</measure>
    <time_frame>up to 100 days after last dose or longer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality</measure>
    <time_frame>Within 28 days prior to first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality</measure>
    <time_frame>Day 1 of Cycles 1-4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality</measure>
    <time_frame>Day 8 of Cycles 1-4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality</measure>
    <time_frame>Day 22 of Cycles 1-4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality</measure>
    <time_frame>Day 29 of Cycles 1-4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality</measure>
    <time_frame>Day 1 of Cycles 5+</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality</measure>
    <time_frame>Day 22 of Cycles 5+</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality</measure>
    <time_frame>up to 100 days after last dose or longer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by Objective Response Rate (ORR)</measure>
    <time_frame>Every 6 weeks for first 4 assessments, then every 12 weeks until disease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by duration of response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Every 6 weeks for first 4 assessments, then every 12 weeks until disease progression</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Clear-cell Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm S: Nivolumab + Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons
Sunitinib 50 mg capsule by mouth on Days 1-28 of 42 day cycle until Progressive disease (PD), toxicity or discontinue for other reasons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm P: Nivolumab + Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 0.3, 2.0 (starting dose), 5.0 mg/kg solution intravenously every 21 days until Progressive disease (PD), toxicity or discontinue for other reasons
Pazopanib 800 mg tablet by mouth daily until Progressive disease (PD), toxicity or discontinue for other reasons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I-1: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg/kg solution intravenously (IV) every 21 days during Induction phase and every 14 days during Maintenance phase until Progressive disease (PD), toxicity or discontinue for other reasons
Ipilimumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase (Ipilimumab will not be administered during Maintenance phase) until Progressive disease (PD), toxicity or discontinue for other reasons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I-3: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase
Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IN-3: Nivolumab+Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase and 3mg/kg solution intravenously (IV) every 14 days during Maintenance phase
Ipilimumab 3mg/kg solution intravenously (IV) every 21 days during Induction phase. Ipilimumab will not be administered during Maintenance phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Arm S: Nivolumab + Sunitinib</arm_group_label>
    <arm_group_label>Arm P: Nivolumab + Pazopanib</arm_group_label>
    <arm_group_label>Arm I-1: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Arm I-3: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Arm IN-3: Nivolumab+Ipilimumab</arm_group_label>
    <other_name>BMS-936558 (MDX-1106)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <arm_group_label>Arm P: Nivolumab + Pazopanib</arm_group_label>
    <other_name>Votrient (Pazopanib hydrochloride)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <arm_group_label>Arm S: Nivolumab + Sunitinib</arm_group_label>
    <other_name>Sutent®</other_name>
    <other_name>Sunitinib Malate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Arm I-1: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Arm I-3: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Arm IN-3: Nivolumab+Ipilimumab</arm_group_label>
    <other_name>YERVOY™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects with histological confirmation of RCC

          -  Advanced or metastatic disease

          -  Measurable disease as defined by RECIST 1.1 criteria

          -  Karnofsky Performance Status (KPS) ≥80%

          -  Available tumor tissue (archival or recent acquisition)

          -  Subjects enrolled in the I-1, I-3 expansion arms and IN-3 addition arms must not have
             received any prior systemic therapy for RCC with the following exceptions:

               1. One prior adjuvant or neoadjuvant therapy for localized or locally advanced RCC
                  is allowed provided recurrence occurred ≥ 6 months after the last dose of the
                  adjuvant or neoadjuvant therapy

               2. Only prior cytokine based treatment for metastatic RCC [eg, interferon-alpha
                  (IFN-alpha) or interleukin 2 (IL-2)] as prior therapy is allowed

        Exclusion Criteria:

          -  Active central nervous system (CNS) metastases

          -  Active or history of autoimmune disease

          -  Ongoing symptomatic cardiac dysrhythmias or uncontrolled atrial fibrillation

          -  History of cerebrovascular accident including transient ischemic attack within the
             past 12 months

          -  History of pulmonary embolism or deep vein thrombosis (DVT) within the past 6 months

          -  Chronic systemic steroids (&gt;10 mg/day Prednisone equivalents) or any other
             immunosuppressive agents

          -  White blood cell (WBC) &lt;2,000/mm3

          -  Neutrophiles &lt;1,500/mm3

          -  Platelets &lt;100,000/mm3

          -  Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) &gt;3x upper limit of
             normal (ULN)

          -  Total Bilirubin &gt;1.5x ULN (except subjects with Gilbert syndrome, total bilirubin &lt;3.0
             mg/dL)

          -  Cardiac ejection fraction &lt;LLN (lower limit of normal)

          -  Serum creatinine &gt;1.5x ULN or creatinine clearance &lt;40 mL/min (Cockroft-Gault formula)

        Exclusion Criteria for Arm S and Arm P only:

          -  For dose escalation cohorts - subjects who received prior Sunitinib or Pazopanib and
             required permanent discontinuation due to toxicity or required dose reduction or delay
             during the first 12 weeks of therapy due to toxicity, or received both prior Sunitinib
             and Pazopanib

          -  Poorly controlled hypertension

          -  Active bleeding or bleeding susceptibility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City Of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, Pllc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bc Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital-Uhn</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2011</study_first_submitted>
  <study_first_submitted_qc>November 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 23, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

